Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Valneva will consolidate its French operations at its Lyon site and close its Nantes location
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
The grants are expected to be received over the next three years, commencing March 2022
Subscribe To Our Newsletter & Stay Updated
